论文部分内容阅读
目的:分析蚓激酶胶囊对脑梗死的干预与预防作用。方法:2013年8月至2014年7月,接收的脑梗死患者,共90例作为本次研究的主要对象。按照随机分组原理,将90例患者分成研究组与对照组,各45例。对照组行基础治疗,研究组在此基础上应用蚓激酶胶囊。观察两组的疗效,同时对比其神经功能的缺损情况。结果:研究组的总有效率为95.56%,对照组为77.78%。研究组明显高于对照组(P<0.05)。研究组加用蚓激酶胶囊后的NIHSS评分为(10.02±4.37)分,对照组为(14.08±5.23)分。研究组的评分明显高于对照组(P<0.05)。结论:对于脑梗死中,应用蚓激酶疗法,效果良好,且利于患者神经功能的恢复。
Objective: To analyze the intervention and preventive effect of lumbrokinase capsule on cerebral infarction. METHODS: From August 2013 to July 2014, a total of 90 patients with cerebral infarction were included as the primary subjects of this study. According to the principle of random grouping, 90 patients were divided into study group and control group, 45 cases each. Control group basic treatment, the research group on the basis of the application of lumbrokinase capsules. The curative effect of the two groups was observed, at the same time compared with the defect of nerve function. Results: The total effective rate was 95.56% in the study group and 77.78% in the control group. The study group was significantly higher than the control group (P <0.05). The NIHSS score of the study group treated with lumbrokinase capsules was (10.02 ± 4.37) points and that of the control group was (14.08 ± 5.23) points. The score of the study group was significantly higher than that of the control group (P <0.05). Conclusion: For cerebral infarction, the application of lumbrokinase therapy, the effect is good, and conducive to the recovery of patients with neurological function.